Autism Center of Excellence, Inc., a non-profit corporation dedicated to the education of children and young adults with autism, announced it has been awarded a $700,000 grant from the Florida Department of Education to plan and develop an autism education center of excellence near Tampa. Florida Autism Center of Excellence (FACE) will apply for a charter and request authorization to serve students in Hillsborough, Pasco, Pinellas, Sarasota, Manatee and Polk counties. The center is scheduled to open in August 2007 and will serve students ages three to 24.
"The Florida Center of Autism Excellence will provide a comprehensive program to address the unmet needs of students with Autism Spectrum Disorders," Mark Claypool, president and chief executive officer of ESA, said. "We believe that children and young adults with autism can advance in their academic and interpersonal skills if they are given the right type of instruction, encouragement and tools to learn in a safe and healthy academic environment.
"Unfortunately, current public education and social programming for students with autism is severely limited by a lack of resources and expertise, and many students simply do not receive the individualized programming that will help them progress from elementary school through high school and transition to post-secondary education," Claypool said. "That's exactly what FACE will provide students in these six counties." child-autism-parent-cafe.com
Click here for more info
Wednesday, December 27, 2006
Wednesday, December 20, 2006
Bush Signs Healthcare Related Bill For Autism
President Bush signed a bill to increase federal funding by 50 percent for the disorder, which afflicts 1.5 million people in the United States. Congress voted to increase federal funding to identify the cause of autism, now diagnosed in one in 166 children. The Senate has also approved a voice vote legislation that authorizes $945 million to National Institutes of Health over five years for autism research, screening and treatment. The institutes would reportedly research areas related to autism spectrum disorder, including an examination of whether the increase in autism diagnoses is caused by environmental factors.
According to Bush, "By creating a national education program for doctors and the public about autism, this legislation will help more people recognize the symptoms of autism." "This will lead to early identification and intervention, which is critical for children with autism," he added. child-autism-parent-cafe.com
Click here for info
According to Bush, "By creating a national education program for doctors and the public about autism, this legislation will help more people recognize the symptoms of autism." "This will lead to early identification and intervention, which is critical for children with autism," he added. child-autism-parent-cafe.com
Click here for info
Thursday, December 14, 2006
The Age of Autism: 'Problems' in CDC data
By Dan Olmsted
UPI Senior Editor
WASHINGTON, Dec. 11 (UPI) -- For three years, the CDC has used a study conducted on its own Vaccine Safety Datalink to reassure parents that mercury in vaccines does not cause autism. Now a panel of government-appointed experts says there are "serious problems" with exactly the approach the CDC took. child-autism-parent-cafe.com
Click here for info
UPI Senior Editor
WASHINGTON, Dec. 11 (UPI) -- For three years, the CDC has used a study conducted on its own Vaccine Safety Datalink to reassure parents that mercury in vaccines does not cause autism. Now a panel of government-appointed experts says there are "serious problems" with exactly the approach the CDC took. child-autism-parent-cafe.com
Click here for info
Monday, December 11, 2006
Autism Expert Advocates Technology at Senate Hearings
Testifying before the Senate Committee on Social Affairs, Science and Technology inquiry on the issue of funding for the treatment of autism Canadian autism expert, Dr. Jeanette Holden, from Queen's University in Kingston, Ontario advocated the use of computer technology as a means to alleviate the problem of providing autism intervention services to families of children with autism.
Dr. Holden is currently undertaking a research trial consisting of 46 families across Ontario, including 63 adult care providers and 52 children aged 2 to 9, using AutismPro. The study is being done in partnership with Autism Ontario and Autism Spectrum Disorder - Canadian American Research Consortium (ASD - CARC) out of Queen's University. Participants have been provided with a one year subscription to the program.
"Early results of our research trial indicate that parents are strongly impressed by AutismPro as a valuable tool for providing care to their children," said Cynthia Howroyd, CEO and President of Virtual Expert Clinics. A speech pathologist who worked with children with autism in New Brunswick. Ms Howroyd developed the online program as a solution to the dilemma of providing timely autism services with limitations in dollars and trained therapists and the startling growth in the disorder. child-autism-parent-cafe.com
Click here for info
Dr. Holden is currently undertaking a research trial consisting of 46 families across Ontario, including 63 adult care providers and 52 children aged 2 to 9, using AutismPro. The study is being done in partnership with Autism Ontario and Autism Spectrum Disorder - Canadian American Research Consortium (ASD - CARC) out of Queen's University. Participants have been provided with a one year subscription to the program.
"Early results of our research trial indicate that parents are strongly impressed by AutismPro as a valuable tool for providing care to their children," said Cynthia Howroyd, CEO and President of Virtual Expert Clinics. A speech pathologist who worked with children with autism in New Brunswick. Ms Howroyd developed the online program as a solution to the dilemma of providing timely autism services with limitations in dollars and trained therapists and the startling growth in the disorder. child-autism-parent-cafe.com
Click here for info
Combating Autism Act Passes House
The National Autism Association (NAA) and SafeMinds are calling the passage of the Combating Autism Act an important step forward for the one in 166 children now diagnosed with autism. The two groups have been involved for the past year and a half with the legislative process to ensure that three main concerns were addressed in the bill:
• Research provisions for investigating the link between environmental factors and the development of autism.
• Greater research oversight from the autism community
• Treatment of those diagnosed with autism spectrum disorders.
In the report language accompanying the bill, Congressman Joe Barton stated, “..the legislation rightfully calls for renewed efforts to study all possible causes of autism—including vaccines and other environmental causes.” Barton also states, “..these provisions will insure continuation and intensification of crucial research at NIEHS so that it is able to conduct all necessary research to determine the environmental factors in autism.” child-autism-parent-cafe
Click here for info
• Research provisions for investigating the link between environmental factors and the development of autism.
• Greater research oversight from the autism community
• Treatment of those diagnosed with autism spectrum disorders.
In the report language accompanying the bill, Congressman Joe Barton stated, “..the legislation rightfully calls for renewed efforts to study all possible causes of autism—including vaccines and other environmental causes.” Barton also states, “..these provisions will insure continuation and intensification of crucial research at NIEHS so that it is able to conduct all necessary research to determine the environmental factors in autism.” child-autism-parent-cafe
Click here for info
Monday, December 04, 2006
New Research Suggests Oxytocin’s Potential for Treatment of Two Core Autism Symptom Domains
American College of Neuropsychopharmacology
Contact: Sharon Reis (202) 745-5103
EMBARGOED FOR RELEASE
9 am EST, December 4, 2006
Study Presented at ACNP Annual Meeting Outlines Effects on Key Symptoms
Nashville, TN, December 4, 2006 – Preliminary new research discussed today at the American College of Neuropsychopharmacology’s Annual Meeting finds that oxytocin, when administered using intravenous fluid and nasal technology may have significant positive effects on adult autism patients. The study, funded by the Seaver Foundation, examined the effects of oxytocin on repetitive behaviors and aspects of social cognition in adults with autism.
Investigators Eric Hollander, MD and Jennifer Bartz, PhD presented results of both intravenous and intranasal administration of oxytocin in high-functioning adult autism patients and discussed the implications of this research for the treatment of autism. Dr. Hollander is Chairman of Psychiatry and at the Mt. Sinai School of Medicine in New York, NY and Director of the Seaver and New York Autism Center of Excellence, one of eight NIH-funded (STAART) centers devoted to the study of autism. Dr. Bartz is a Post Doctoral Fellow at the Seaver Center at the Mt., Sinai School of Medicine.
“Studies with animals have found that oxytocin plays a role in a variety of behaviors, including parent-child and adult-to-adult pair bonding, social memory, social cognition, anxiety reduction and repetitive behaviors,” explained Dr. Bartz. “However,” adds Dr. Hollander, “we have only recently considered that administration of oxytocin can have behavioral effects. Autism is a particularly ripe neuropsychiatric disorder for studying this approach because it presents with the types of symptoms that have been found to be associated with the oxytocin system.”
High-functioning adults with autism or Asperger’s disorder received an intravenous infusion of pitocin (synthetic oxytocin) or placebo (saline solution) over a four-hour period. During that time, participants were monitored for repetitive behaviors that are hallmarks of autism spectrum disorders including need to tell/ask, touching, and repeating. These behaviors were assessed at a baseline and throughout the course of the infusion.
“Repetitive behaviors are often overlooked as symptoms of autism in favor of more dramatic symptoms like disrupted social functioning,” noted Hollander. “However, early repetitive behavior is often the best predictor of a later autism diagnosis.”
The infusion produced results that were both clinically and statistically significant. Hollander noted a rapid reduction of repetitive behaviors over the course of the oxytocin infusion, whereas no such reduction occurred following the placebo infusion, suggesting that oxytocin does indeed address these symptoms.
Researchers also looked at the effects of oxytocin on social cognition. Autism patients are often unable to detect or read emotion in others through facial and voice cues, resulting in the decreased ability to have meaningful interactions with others that characterizes individuals with this disease.
To test participants’ ability to assign affective significance to speech, participants listened to pre-recorded sentences with neutral semantic content that were presented with different intonations such as anger, sadness, or happiness. Participants were asked to identify the emotion. Participants received intravenous infusions of pitocin (synthetic oxytocin) or placebo (saline solution) over a four-hour period; participants then returned approximately two weeks later, receiving the alternate compound. Comprehension of affective speech was assessed throughout the four-hour infusion on both occasions, that is, once with intravenous infusion of oxytocin and once without.
Most interestingly, participants who received oxytocin on the first testing day retained the ability to assign affective significance to speech, performing above expectations when they returned approximately two weeks later. This effect was not found among participants who received the placebo on the first testing day.
Hollander and his colleagues are now using nasal technology to study the treatment implications of oxytocin in a controlled six week trial. “The intranasal administration of oxytocin is important because it may allow for better penetration of the blood brain barrier, and is easier to administer,” explained Hollander. “When administered orally, oxytocin is metabolized and only a small amount reaches the brain. This is important because the behavioral effects of oxytocin are thought to result from its action on the brain.”
Hollander and his colleagues are among the first group to have used intravenous fluid technology and nasal technology to study the behavioral effects of oxytocin in autism spectrum disorders. Though the findings are promising, Hollander cautions that this research is still very preliminary.
“Our findings will need to be replicated in large scale, placebo controlled trials to fully explore treatment potential,” said Hollander. “And, though both intravenous and intranasal approaches have been well tolerated, we need to understand more about the safety of these potential treatments, particularly before these effects are explored in autistic children.”
ACNP is holding its Annual Meeting December 3 – 7, 2006, in Hollywood, FL.
ACNP, founded in 1961, is a professional organization of more than 700 leading scientists, including three Nobel Laureates. The mission of ACNP is to further research and education in neuropsychopharmacology and related fields in the following ways: promoting the interaction of a broad range of scientific disciplines of brain and behavior in order to advance the understanding of prevention and treatment of disease of the nervous system including psychiatric, neurological, behavioral and addictive disorders; encouraging scientists to enter research careers in fields related to these disorders and their treatment; and ensuring the dissemination of relevant scientific advances. A non-profit organization, ACNP receives revenues from a variety of sources including membership dues, publication sales, registration fees, and pharmaceutical industry grants.
# # #
child-autism-parent-cafe.com
Contact: Sharon Reis (202) 745-5103
EMBARGOED FOR RELEASE
9 am EST, December 4, 2006
Study Presented at ACNP Annual Meeting Outlines Effects on Key Symptoms
Nashville, TN, December 4, 2006 – Preliminary new research discussed today at the American College of Neuropsychopharmacology’s Annual Meeting finds that oxytocin, when administered using intravenous fluid and nasal technology may have significant positive effects on adult autism patients. The study, funded by the Seaver Foundation, examined the effects of oxytocin on repetitive behaviors and aspects of social cognition in adults with autism.
Investigators Eric Hollander, MD and Jennifer Bartz, PhD presented results of both intravenous and intranasal administration of oxytocin in high-functioning adult autism patients and discussed the implications of this research for the treatment of autism. Dr. Hollander is Chairman of Psychiatry and at the Mt. Sinai School of Medicine in New York, NY and Director of the Seaver and New York Autism Center of Excellence, one of eight NIH-funded (STAART) centers devoted to the study of autism. Dr. Bartz is a Post Doctoral Fellow at the Seaver Center at the Mt., Sinai School of Medicine.
“Studies with animals have found that oxytocin plays a role in a variety of behaviors, including parent-child and adult-to-adult pair bonding, social memory, social cognition, anxiety reduction and repetitive behaviors,” explained Dr. Bartz. “However,” adds Dr. Hollander, “we have only recently considered that administration of oxytocin can have behavioral effects. Autism is a particularly ripe neuropsychiatric disorder for studying this approach because it presents with the types of symptoms that have been found to be associated with the oxytocin system.”
High-functioning adults with autism or Asperger’s disorder received an intravenous infusion of pitocin (synthetic oxytocin) or placebo (saline solution) over a four-hour period. During that time, participants were monitored for repetitive behaviors that are hallmarks of autism spectrum disorders including need to tell/ask, touching, and repeating. These behaviors were assessed at a baseline and throughout the course of the infusion.
“Repetitive behaviors are often overlooked as symptoms of autism in favor of more dramatic symptoms like disrupted social functioning,” noted Hollander. “However, early repetitive behavior is often the best predictor of a later autism diagnosis.”
The infusion produced results that were both clinically and statistically significant. Hollander noted a rapid reduction of repetitive behaviors over the course of the oxytocin infusion, whereas no such reduction occurred following the placebo infusion, suggesting that oxytocin does indeed address these symptoms.
Researchers also looked at the effects of oxytocin on social cognition. Autism patients are often unable to detect or read emotion in others through facial and voice cues, resulting in the decreased ability to have meaningful interactions with others that characterizes individuals with this disease.
To test participants’ ability to assign affective significance to speech, participants listened to pre-recorded sentences with neutral semantic content that were presented with different intonations such as anger, sadness, or happiness. Participants were asked to identify the emotion. Participants received intravenous infusions of pitocin (synthetic oxytocin) or placebo (saline solution) over a four-hour period; participants then returned approximately two weeks later, receiving the alternate compound. Comprehension of affective speech was assessed throughout the four-hour infusion on both occasions, that is, once with intravenous infusion of oxytocin and once without.
Most interestingly, participants who received oxytocin on the first testing day retained the ability to assign affective significance to speech, performing above expectations when they returned approximately two weeks later. This effect was not found among participants who received the placebo on the first testing day.
Hollander and his colleagues are now using nasal technology to study the treatment implications of oxytocin in a controlled six week trial. “The intranasal administration of oxytocin is important because it may allow for better penetration of the blood brain barrier, and is easier to administer,” explained Hollander. “When administered orally, oxytocin is metabolized and only a small amount reaches the brain. This is important because the behavioral effects of oxytocin are thought to result from its action on the brain.”
Hollander and his colleagues are among the first group to have used intravenous fluid technology and nasal technology to study the behavioral effects of oxytocin in autism spectrum disorders. Though the findings are promising, Hollander cautions that this research is still very preliminary.
“Our findings will need to be replicated in large scale, placebo controlled trials to fully explore treatment potential,” said Hollander. “And, though both intravenous and intranasal approaches have been well tolerated, we need to understand more about the safety of these potential treatments, particularly before these effects are explored in autistic children.”
ACNP is holding its Annual Meeting December 3 – 7, 2006, in Hollywood, FL.
ACNP, founded in 1961, is a professional organization of more than 700 leading scientists, including three Nobel Laureates. The mission of ACNP is to further research and education in neuropsychopharmacology and related fields in the following ways: promoting the interaction of a broad range of scientific disciplines of brain and behavior in order to advance the understanding of prevention and treatment of disease of the nervous system including psychiatric, neurological, behavioral and addictive disorders; encouraging scientists to enter research careers in fields related to these disorders and their treatment; and ensuring the dissemination of relevant scientific advances. A non-profit organization, ACNP receives revenues from a variety of sources including membership dues, publication sales, registration fees, and pharmaceutical industry grants.
# # #
child-autism-parent-cafe.com
Study: Oxytocin’s Potential for Treatment of Two Core Autism Symptom Domains
American College of Neuropsychopharmacology
Contact: Sharon Reis (202) 745-5103
EMBARGOED FOR RELEASE
9 am EST, December 4, 2006
New Research Suggests Oxytocin’s Potential for Treatment of Two Core Autism
Symptom Domains
Study Presented at ACNP Annual Meeting Outlines Effects on Key Symptoms
Nashville, TN, December 4, 2006 – Preliminary new research discussed today at the American College of Neuropsychopharmacology’s Annual Meeting finds that oxytocin, when administered using intravenous fluid and nasal technology may have significant positive effects on adult autism patients. The study, funded by the Seaver Foundation, examined the effects of oxytocin on repetitive behaviors and aspects of social cognition in adults with autism.
Investigators Eric Hollander, MD and Jennifer Bartz, PhD presented results of both intravenous and intranasal administration of oxytocin in high-functioning adult autism patients and discussed the implications of this research for the treatment of autism. Dr. Hollander is Chairman of Psychiatry and at the Mt. Sinai School of Medicine in New York, NY and Director of the Seaver and New York Autism Center of Excellence, one of eight NIH-funded (STAART) centers devoted to the study of autism. Dr. Bartz is a Post Doctoral Fellow at the Seaver Center at the Mt., Sinai School of Medicine.
“Studies with animals have found that oxytocin plays a role in a variety of behaviors, including parent-child and adult-to-adult pair bonding, social memory, social cognition, anxiety reduction and repetitive behaviors,” explained Dr. Bartz. “However,” adds Dr. Hollander, “we have only recently considered that administration of oxytocin can have behavioral effects. Autism is a particularly ripe neuropsychiatric disorder for studying this approach because it presents with the types of symptoms that have been found to be associated with the oxytocin system.”
High-functioning adults with autism or Asperger’s disorder received an intravenous infusion of pitocin (synthetic oxytocin) or placebo (saline solution) over a four-hour period. During that time, participants were monitored for repetitive behaviors that are hallmarks of autism spectrum disorders including need to tell/ask, touching, and repeating. These behaviors were assessed at a baseline and throughout the course of the infusion.
“Repetitive behaviors are often overlooked as symptoms of autism in favor of more dramatic symptoms like disrupted social functioning,” noted Hollander. “However, early repetitive behavior is often the best predictor of a later autism diagnosis.”
The infusion produced results that were both clinically and statistically significant. Hollander noted a rapid reduction of repetitive behaviors over the course of the oxytocin infusion, whereas no such reduction occurred following the placebo infusion, suggesting that oxytocin does indeed address these symptoms.
Researchers also looked at the effects of oxytocin on social cognition. Autism patients are often unable to detect or read emotion in others through facial and voice cues, resulting in the decreased ability to have meaningful interactions with others that characterizes individuals with this disease.
To test participants’ ability to assign affective significance to speech, participants listened to pre-recorded sentences with neutral semantic content that were presented with different intonations such as anger, sadness, or happiness. Participants were asked to identify the emotion. Participants received intravenous infusions of pitocin (synthetic oxytocin) or placebo (saline solution) over a four-hour period; participants then returned approximately two weeks later, receiving the alternate compound. Comprehension of affective speech was assessed throughout the four-hour infusion on both occasions, that is, once with intravenous infusion of oxytocin and once without.
Most interestingly, participants who received oxytocin on the first testing day retained the ability to assign affective significance to speech, performing above expectations when they returned approximately two weeks later. This effect was not found among participants who received the placebo on the first testing day.
Hollander and his colleagues are now using nasal technology to study the treatment implications of oxytocin in a controlled six week trial. “The intranasal administration of oxytocin is important because it may allow for better penetration of the blood brain barrier, and is easier to administer,” explained Hollander. “When administered orally, oxytocin is metabolized and only a small amount reaches the brain. This is important because the behavioral effects of oxytocin are thought to result from its action on the brain.”
Hollander and his colleagues are among the first group to have used intravenous fluid technology and nasal technology to study the behavioral effects of oxytocin in autism spectrum disorders. Though the findings are promising, Hollander cautions that this research is still very preliminary.
“Our findings will need to be replicated in large scale, placebo controlled trials to fully explore treatment potential,” said Hollander. “And, though both intravenous and intranasal approaches have been well tolerated, we need to understand more about the safety of these potential treatments, particularly before these effects are explored in autistic children.”
ACNP is holding its Annual Meeting December 3 – 7, 2006, in Hollywood, FL.
ACNP, founded in 1961, is a professional organization of more than 700 leading scientists, including three Nobel Laureates. The mission of ACNP is to further research and education in neuropsychopharmacology and related fields in the following ways: promoting the interaction of a broad range of scientific disciplines of brain and behavior in order to advance the understanding of prevention and treatment of disease of the nervous system including psychiatric, neurological, behavioral and addictive disorders; encouraging scientists to enter research careers in fields related to these disorders and their treatment; and ensuring the dissemination of relevant scientific advances. A non-profit organization, ACNP receives revenues from a variety of sources including membership dues, publication sales, registration fees, and pharmaceutical industry grants.
# # #
child-autism-parent-cafe.com
Contact: Sharon Reis (202) 745-5103
EMBARGOED FOR RELEASE
9 am EST, December 4, 2006
New Research Suggests Oxytocin’s Potential for Treatment of Two Core Autism
Symptom Domains
Study Presented at ACNP Annual Meeting Outlines Effects on Key Symptoms
Nashville, TN, December 4, 2006 – Preliminary new research discussed today at the American College of Neuropsychopharmacology’s Annual Meeting finds that oxytocin, when administered using intravenous fluid and nasal technology may have significant positive effects on adult autism patients. The study, funded by the Seaver Foundation, examined the effects of oxytocin on repetitive behaviors and aspects of social cognition in adults with autism.
Investigators Eric Hollander, MD and Jennifer Bartz, PhD presented results of both intravenous and intranasal administration of oxytocin in high-functioning adult autism patients and discussed the implications of this research for the treatment of autism. Dr. Hollander is Chairman of Psychiatry and at the Mt. Sinai School of Medicine in New York, NY and Director of the Seaver and New York Autism Center of Excellence, one of eight NIH-funded (STAART) centers devoted to the study of autism. Dr. Bartz is a Post Doctoral Fellow at the Seaver Center at the Mt., Sinai School of Medicine.
“Studies with animals have found that oxytocin plays a role in a variety of behaviors, including parent-child and adult-to-adult pair bonding, social memory, social cognition, anxiety reduction and repetitive behaviors,” explained Dr. Bartz. “However,” adds Dr. Hollander, “we have only recently considered that administration of oxytocin can have behavioral effects. Autism is a particularly ripe neuropsychiatric disorder for studying this approach because it presents with the types of symptoms that have been found to be associated with the oxytocin system.”
High-functioning adults with autism or Asperger’s disorder received an intravenous infusion of pitocin (synthetic oxytocin) or placebo (saline solution) over a four-hour period. During that time, participants were monitored for repetitive behaviors that are hallmarks of autism spectrum disorders including need to tell/ask, touching, and repeating. These behaviors were assessed at a baseline and throughout the course of the infusion.
“Repetitive behaviors are often overlooked as symptoms of autism in favor of more dramatic symptoms like disrupted social functioning,” noted Hollander. “However, early repetitive behavior is often the best predictor of a later autism diagnosis.”
The infusion produced results that were both clinically and statistically significant. Hollander noted a rapid reduction of repetitive behaviors over the course of the oxytocin infusion, whereas no such reduction occurred following the placebo infusion, suggesting that oxytocin does indeed address these symptoms.
Researchers also looked at the effects of oxytocin on social cognition. Autism patients are often unable to detect or read emotion in others through facial and voice cues, resulting in the decreased ability to have meaningful interactions with others that characterizes individuals with this disease.
To test participants’ ability to assign affective significance to speech, participants listened to pre-recorded sentences with neutral semantic content that were presented with different intonations such as anger, sadness, or happiness. Participants were asked to identify the emotion. Participants received intravenous infusions of pitocin (synthetic oxytocin) or placebo (saline solution) over a four-hour period; participants then returned approximately two weeks later, receiving the alternate compound. Comprehension of affective speech was assessed throughout the four-hour infusion on both occasions, that is, once with intravenous infusion of oxytocin and once without.
Most interestingly, participants who received oxytocin on the first testing day retained the ability to assign affective significance to speech, performing above expectations when they returned approximately two weeks later. This effect was not found among participants who received the placebo on the first testing day.
Hollander and his colleagues are now using nasal technology to study the treatment implications of oxytocin in a controlled six week trial. “The intranasal administration of oxytocin is important because it may allow for better penetration of the blood brain barrier, and is easier to administer,” explained Hollander. “When administered orally, oxytocin is metabolized and only a small amount reaches the brain. This is important because the behavioral effects of oxytocin are thought to result from its action on the brain.”
Hollander and his colleagues are among the first group to have used intravenous fluid technology and nasal technology to study the behavioral effects of oxytocin in autism spectrum disorders. Though the findings are promising, Hollander cautions that this research is still very preliminary.
“Our findings will need to be replicated in large scale, placebo controlled trials to fully explore treatment potential,” said Hollander. “And, though both intravenous and intranasal approaches have been well tolerated, we need to understand more about the safety of these potential treatments, particularly before these effects are explored in autistic children.”
ACNP is holding its Annual Meeting December 3 – 7, 2006, in Hollywood, FL.
ACNP, founded in 1961, is a professional organization of more than 700 leading scientists, including three Nobel Laureates. The mission of ACNP is to further research and education in neuropsychopharmacology and related fields in the following ways: promoting the interaction of a broad range of scientific disciplines of brain and behavior in order to advance the understanding of prevention and treatment of disease of the nervous system including psychiatric, neurological, behavioral and addictive disorders; encouraging scientists to enter research careers in fields related to these disorders and their treatment; and ensuring the dissemination of relevant scientific advances. A non-profit organization, ACNP receives revenues from a variety of sources including membership dues, publication sales, registration fees, and pharmaceutical industry grants.
# # #
child-autism-parent-cafe.com
Friday, December 01, 2006
Students with Disabilities Entitled to School Transportation When Home District Closed
Students with Disabilities are Entitled to Transportation to School Programs Even When the Home District is Closed
November 2006 - Did you know that students with disabilities who are placed in out of district programs by the Committee on Special Education (CSE) or the Preschool Committee on Special Education (CPSE) are entitled to transportation to that program even when the home district is closed? In other words, students who have special education placements, documented on their Individualized Education Program (IEP), should be transported to these placements everyday the program is open even if the home district is closed (snow days are an acceptable exception).
Section 4402(4)(d) of the Education Law specifies that a child identified by the Committee on Special Education as needing a placement outside of the district of residence shall be provided transportation to this placement. Nowhere in this section does it give the district authority to limit transportation to only those days that the district is in session.
If you are aware of a family being denied transportation to an approved placement, please send a completed intake form (attached to this letter) to:
Robin Worobey
Developmental Disabilities Planning Council
155 Washington Avenue, Albany, NY 12210-2329
(518) 486-7505 or fax (518) 402-3505
rworobey@ddpc.state.ny.us
The DDPC also request that those families that are currently struggling with denial of transportation share their personal stories in a letter. These letters will be collected and used to obtain a statewide resolution to this problem.
For clarification, we are not talking about students who are attending a non-public school selected by parents at the parent’s expense.
child-autism-parent-cafe.com
November 2006 - Did you know that students with disabilities who are placed in out of district programs by the Committee on Special Education (CSE) or the Preschool Committee on Special Education (CPSE) are entitled to transportation to that program even when the home district is closed? In other words, students who have special education placements, documented on their Individualized Education Program (IEP), should be transported to these placements everyday the program is open even if the home district is closed (snow days are an acceptable exception).
Section 4402(4)(d) of the Education Law specifies that a child identified by the Committee on Special Education as needing a placement outside of the district of residence shall be provided transportation to this placement. Nowhere in this section does it give the district authority to limit transportation to only those days that the district is in session.
If you are aware of a family being denied transportation to an approved placement, please send a completed intake form (attached to this letter) to:
Robin Worobey
Developmental Disabilities Planning Council
155 Washington Avenue, Albany, NY 12210-2329
(518) 486-7505 or fax (518) 402-3505
rworobey@ddpc.state.ny.us
The DDPC also request that those families that are currently struggling with denial of transportation share their personal stories in a letter. These letters will be collected and used to obtain a statewide resolution to this problem.
For clarification, we are not talking about students who are attending a non-public school selected by parents at the parent’s expense.
child-autism-parent-cafe.com
Subscribe to:
Posts (Atom)
